Replies to post #17188 on Synaptogenix Inc (SNPX)

[runncoach]

I have and that's why Dr Alkon points Althira out in all his presentations. Their MOA affects the hepatocyte growth factor (HGF)/MET receptor system. Their drug is a molecule that increases/impacts those levels. Bryostatin also impacts that same pathway as well as other proven beneficial growth factors such as bdnf, igf, ngf, and others. Althira IMO has a shot of providing benefit to patients but if their molecule benefits that pathway, the other factors I just mentioned would seemingly repair synaptic damage more extensively IMO.